Format
Sort by
Items per page

Send to

Choose Destination

Best matches for APOC3 and Heart:

A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels. Khetarpal SA et al. Nat Med. (2017)

Loss-of-function mutations in APOC3, triglycerides, and coronary disease. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. et al. N Engl J Med. (2014)

Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. Jørgensen AB et al. N Engl J Med. (2014)

Search results

Items: 1 to 20 of 78

1.

Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in type 1 diabetes.

Basu A, Bebu I, Jenkins AJ, Stoner JA, Zhang Y, Klein RL, Lopes-Virella MF, Garvey WT, Budoff MJ, Alaupovic P, Lyons TJ.

J Lipid Res. 2019 Jun 15. pii: jlr.P090647. doi: 10.1194/jlr.P090647. [Epub ahead of print]

2.

Depletion of β3-adrenergic receptor induces left ventricular diastolic dysfunction via potential regulation of energy metabolism and cardiac contraction.

Yang W, Wei X, Su X, Shen Y, Jin W, Fang Y.

Gene. 2019 May 20;697:1-10. doi: 10.1016/j.gene.2019.02.038. Epub 2019 Feb 19.

PMID:
30790654
3.

Apolipoprotein C-III Strongly Correlates with Activated Factor VII-Anti-Thrombin Complex: An Additional Link between Plasma Lipids and Coagulation.

Martinelli N, Baroni M, Castagna A, Lunghi B, Stefanoni F, Tosi F, Croce J, Udali S, Woodhams B, Girelli D, Bernardi F, Olivieri O.

Thromb Haemost. 2019 Feb;119(2):192-202. doi: 10.1055/s-0038-1676817. Epub 2019 Jan 2.

PMID:
30602199
4.

Endothelial Lipase Is an Alternative Pathway for Fatty Acid Release from Lipoproteins: Evidence from a High Fat Diet Model of Obesity in Rats.

Barchuk M, Miksztowicz V, Zago V, Cevey A, López G, Goren N, Friedman S, Gelpi RJ, Morales C, Fernandez Tomé MDC, Schreier L, Berg G.

Lipids. 2018 Oct;53(10):993-1003. doi: 10.1002/lipd.12107.

PMID:
30592063
5.

Aerobic exercise reduces triglycerides by targeting apolipoprotein C3 in patients with coronary heart disease.

Wang Y, Shen L, Xu D.

Clin Cardiol. 2019 Jan;42(1):56-61. doi: 10.1002/clc.23104. Epub 2018 Dec 21.

6.

Cohort-wide deep whole genome sequencing and the allelic architecture of complex traits.

Gilly A, Suveges D, Kuchenbaecker K, Pollard M, Southam L, Hatzikotoulas K, Farmaki AE, Bjornland T, Waples R, Appel EVR, Casalone E, Melloni G, Kilian B, Rayner NW, Ntalla I, Kundu K, Walter K, Danesh J, Butterworth A, Barroso I, Tsafantakis E, Dedoussis G, Moltke I, Zeggini E.

Nat Commun. 2018 Nov 7;9(1):4674. doi: 10.1038/s41467-018-07070-8. Erratum in: Nat Commun. 2018 Dec 19;9(1):5460.

7.

Association of Multiple Genetic Variants with the Extension and Severity of Coronary Artery Disease.

Fischer SCPM, Pinto SP, Lins LCDAS, Bianco HT, Monteiro CMC, Pinheiro LFM, Fonseca FAH, Izar MCO.

Arq Bras Cardiol. 2018 Jan;110(1):16-23. doi: 10.5935/abc.20170177. Epub 2018 Feb 1. English, Portuguese.

8.

APOC3 Loss-of-Function Mutations, Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Cardiovascular Risk: Mediation- and Meta-Analyses of 137 895 Individuals.

Wulff AB, Nordestgaard BG, Tybjærg-Hansen A.

Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):660-668. doi: 10.1161/ATVBAHA.117.310473. Epub 2018 Jan 18.

PMID:
29348120
9.

A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.

Khetarpal SA, Zeng X, Millar JS, Vitali C, Somasundara AVH, Zanoni P, Landro JA, Barucci N, Zavadoski WJ, Sun Z, de Haard H, Toth IV, Peloso GM, Natarajan P, Cuchel M, Lund-Katz S, Phillips MC, Tall AR, Kathiresan S, DaSilva-Jardine P, Yates NA, Rader DJ.

Nat Med. 2017 Sep;23(9):1086-1094. doi: 10.1038/nm.4390. Epub 2017 Aug 21.

10.

Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL.

Larsson M, Allan CM, Jung RS, Heizer PJ, Beigneux AP, Young SG, Fong LG.

J Lipid Res. 2017 Sep;58(9):1893-1902. doi: 10.1194/jlr.M078220. Epub 2017 Jul 10.

11.

Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity.

Saleheen D, Natarajan P, Armean IM, Zhao W, Rasheed A, Khetarpal SA, Won HH, Karczewski KJ, O'Donnell-Luria AH, Samocha KE, Weisburd B, Gupta N, Zaidi M, Samuel M, Imran A, Abbas S, Majeed F, Ishaq M, Akhtar S, Trindade K, Mucksavage M, Qamar N, Zaman KS, Yaqoob Z, Saghir T, Rizvi SNH, Memon A, Hayyat Mallick N, Ishaq M, Rasheed SZ, Memon FU, Mahmood K, Ahmed N, Do R, Krauss RM, MacArthur DG, Gabriel S, Lander ES, Daly MJ, Frossard P, Danesh J, Rader DJ, Kathiresan S.

Nature. 2017 Apr 12;544(7649):235-239. doi: 10.1038/nature22034.

12.

Using human genetics to discover new therapeutic targets for plasma lipids.

Cohen JC.

J Intern Med. 2016 Nov;280(5):487-495. doi: 10.1111/joim.12521. Epub 2016 Oct 14. Review.

13.
14.

Phenotypic variability in 4 homozygous familial hypercholesterolemia siblings compound heterozygous for LDLR mutations.

Rabacchi C, Bigazzi F, Puntoni M, Sbrana F, Sampietro T, Tarugi P, Bertolini S, Calandra S.

J Clin Lipidol. 2016 Jul-Aug;10(4):944-952.e1. doi: 10.1016/j.jacl.2016.04.005. Epub 2016 Apr 21.

PMID:
27578127
15.

Apolipoprotein C3 gene variants and the risk of coronary heart disease: A meta-analysis.

Li Y, Li C, Gao J.

Meta Gene. 2016 Apr 23;9:104-9. doi: 10.1016/j.mgene.2016.04.004. eCollection 2016 Sep. Review.

16.

Plasma-derived Extracellular Vesicles Contain Predictive Biomarkers and Potential Therapeutic Targets for Myocardial Ischemic (MI) Injury.

Cheow ES, Cheng WC, Lee CN, de Kleijn D, Sorokin V, Sze SK.

Mol Cell Proteomics. 2016 Aug;15(8):2628-40. doi: 10.1074/mcp.M115.055731. Epub 2016 May 27.

17.

Novel APOB missense variants, A224T and V925L, in a black South African woman with marked hypocholesterolemia.

Miller SA, Hooper AJ, Mantiri GA, Marais D, Tanyanyiwa DM, McKnight J, Burnett JR.

J Clin Lipidol. 2016 May-Jun;10(3):604-9. doi: 10.1016/j.jacl.2016.01.006. Epub 2016 Feb 16.

PMID:
27206948
18.

Targeted exonic sequencing of GWAS loci in the high extremes of the plasma lipids distribution.

Patel AP, Peloso GM, Pirruccello JP, Johansen CT, Dubé JB, Larach DB, Ban MR, Dallinge-Thie GM, Gupta N, Boehnke M, Abecasis GR, Kastelein JJ, Hovingh GK, Hegele RA, Rader DJ, Kathiresan S.

Atherosclerosis. 2016 Jul;250:63-8. doi: 10.1016/j.atherosclerosis.2016.04.011. Epub 2016 Apr 23.

19.

Metabolic Characterization of a Rare Genetic Variation Within APOC3 and Its Lipoprotein Lipase-Independent Effects.

Drenos F, Davey Smith G, Ala-Korpela M, Kettunen J, Würtz P, Soininen P, Kangas AJ, Dale C, Lawlor DA, Gaunt TR, Casas JP, Timpson NJ.

Circ Cardiovasc Genet. 2016 Jun;9(3):231-9. doi: 10.1161/CIRCGENETICS.115.001302. Epub 2016 Apr 25.

20.

Replication of association of the apolipoprotein A1-C3-A4 gene cluster with the risk of gout.

Rasheed H, Phipps-Green AJ, Topless R, Smith MD, Hill C, Lester S, Rischmueller M, Janssen M, Jansen TL, Joosten LA, Radstake TR, Riches PL, Tausche AK, Lioté F, So A, van Rij A, Jones GT, McCormick SP, Harrison AA, Stamp LK, Dalbeth N, Merriman TR.

Rheumatology (Oxford). 2016 Aug;55(8):1421-30. doi: 10.1093/rheumatology/kew057. Epub 2016 Apr 18.

Supplemental Content

Loading ...
Support Center